Biomet completes $1B debt offering; J&J wins 510(k) for adaptable surgical shears;

 @FierceMedDev: One way to address device hacking? A wrist-watch-like device that measures biometrics as a kind of security I.D. More  | Follow @FierceMedDev

 @MarkHFierce: CardioDx gained a crucial win: Medicare coverage for a coronary artery disease test. More | Follow @MarkHFierce

 @DamianFierce: In keeping with its plans to slim down, Boston Scientific is cutting 50 jobs in Ireland. More | Follow @DamianFierce

> The University of Minnesota's Medical Devices Center, which has filed 109 invention disclosures since is 2008 launch, is pursuing a $2.2 million expansion. Story

> Exact Sciences ($EXAS) is announcing plans for a public offering of common stock, likely sometime this month, according to a regulatory filing. Release

> Johnson & Johnson's Ethicon Endo-Surgery unit won a 510(k) clearance for new surgical shears that can adapt to handle tasks including dissection, sealing, transection and otomy creation. Release

> The European market for polymers in medical devices should surpass $1.3 billion by 2018 as the substance is increasingly used as a manufacturing ingredient, a new Frost & Sullivan report concludes. Release

> The 18th annual BIO-Europe conference will be held in Hamburg, Germany from Nov. 12-14, 2012 at the CCH Congress Center. The networking event is a major draw for medical device, biotech and pharmaceutical companies. Release

> Biomet ($BMET) says it has completed a $1 billion debt offering designed, in part, for refinancing purposes. Release

> Codman & Shurtleff snagged FDA approval for its Medstream Programmable Infusion System, an implantable infusion pump and catheter system designed to treat movement disorders caused by spinal injury. Item

> Diagnostics firm GenMark ($GNMK) reported a more than 300% revenue increase in Q2, crediting more placements and a burgeoning reagent business. More

> The Taiwanese medical device market is poised to top $3.3 billion this year and expand to $4 billion in 2013, one executive says. News

> Pfizer ($PFE) has obtained exclusive rights from Mylan to market and sell EpiPen products in Japan--devices that enable self-administered emergency treatment for life-threatening allergic reactions. Release

Biotech News

 @FierceBiotech: Fuji Pharma jumps into CMO game with $53.4M plant buy. More | Follow @FierceBiotech

 @JohnCFierce: Lundbeck's Phase II Alzheimer's drug that boosts cognition chemicals looks interesting. Harder to do deals now post-bapi? More | Follow @JohnCFierce

 @RyanMFierce: Lots of a Big Pharma news this week, mostly bad. How about some startup action? Good or bad. | Follow @RyanMFierce

> Novartis keeps U.K. respiratory unit after layoffs. Item

> Billionaire's biotech seals second deal with Synthetic Biologics. News

> AstraZeneca pulls the plug on sepsis drug after trial tanks. News

> Infinity Pharma axes 20% of jobs. Story

Pharma News

 @FiercePharma: Generics trounced Big Pharma's Q2 results. Who benefited? Our 11 Fastest-Growing Generics Companies. Special Report | Follow @FiercePharma

> Lundbeck eyes Alzheimer's partners as H1 sales stumble. Article

> DoJ hasn't given up on prosecuting execs for pharma misdoings. More

> Dissatisfied by buyout bids, Warner Chilcott opts for $1B dividend instead. Story

Biomarkers News

> Faster BRCA mutation identification could help families at risk. Story

> Prostate gene deficit could boost tumor growth. Item

> Brain signals when 'Special K' will do the trick. More

> Researchers find East Asian TKI resistance gene. Article

Drug Delivery News

> U.S. submission for Durect's Posidur is in the works. More

> Pluristem PLX cells turn around near fatal bone marrow failure. Article

> Endocyte's kidney conjugates get right to the spot. Story

> Swimming microbots could deliver drugs. Item

> Talon pins its hopes on Marqibo FDA approval. Report